← All trials
NCT06132243
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2023
- Primary completion
- Feb 29, 2024
- Completion date
- Jul 31, 2024
- First posted
- Nov 15, 2023
- Last posted
- Nov 15, 2023
- Enrollment
- 48
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Suzhou Zelgen Biopharmaceuticals Co.,LtdLead sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,LtdStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.